Plain-English translation of NCT06413342 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a medication called as a next step after older adults with esophageal cancer have finished their standard radiation and chemotherapy treatment. The medication is an immunotherapy—a type of drug that helps your immune system fight cancer cells. Researchers want to see if this medication can prevent the cancer from coming back and help patients live longer.
After radiation and chemotherapy, some patients with esophageal cancer stay cancer-free, while others experience a return of their disease. This trial exists to find out whether giving this medication afterward can reduce the chances of cancer returning and improve survival in older patients who may have fewer treatment options.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. One group receives the medication as an injection into a vein every 3 weeks for up to 12 months, with doses adjusted based on your weight; the other group receives standard follow-up care and observation without the medication. All participants will have regular clinic visits and blood tests to check how well the treatment is working and to monitor for any side effects. The study will track how long you survive and whether your cancer returns.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
China